Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PADCEV vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA-approved: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.,Off-label: None established.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with Ig G1 clearance.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
The small molecule MMAE is metabolized primarily by CYP3A4. Enfortumab, the antibody component, is catabolized to small peptides and amino acids.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
No specific protein binding data; as a monoclonal antibody, it is not highly bound to plasma proteins (expected <10%).
Approximately 85-90% bound to serum albumin.
Approximately 0.07 L/kg (7.0 L in 70 kg patient), indicating limited extravascular distribution and consistent with distribution into vascular and interstitial spaces.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Administered intravenously only; bioavailability 100% by IV route.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73m2). Use not recommended in severe renal impairment (e GFR <30 m L/min/1.73m2) or ESRD.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
No formal studies; mild (Child-Pugh A) and moderate (Child-Pugh B) may use with caution; not recommended in severe (Child-Pugh C).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and effectiveness in pediatric patients have not been established.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended based on age alone; monitor closely for adverse effects due to potential comorbidities and polypharmacy.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: SERIOUS SKIN REACTIONS. PADCEV can cause severe, life-threatening or fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Discontinue PADCEV immediately if signs or symptoms of SJS or TEN occur and permanently discontinue if confirmed.
None.
Cutaneous adverse reactions: Monitor for severe skin reactions; interrupt or discontinue as appropriate.,Hyperglycemia: Monitor blood glucose levels, especially in patients with diabetes or risk factors; manage with antihyperglycemics.,Ocular disorders: May cause keratitis, dry eye, or blurred vision; monitor and refer to ophthalmologist.,Peripheral neuropathy: Monitor for new or worsening neuropathy; dose adjustment may be required.,Pneumonitis or interstitial lung disease: Monitor for signs and symptoms; discontinue if confirmed.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
None.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions reported. However, patients should maintain adequate hydration. Avoid grapefruit and grapefruit juice if taking concurrent CYP3A4 substrates.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Advise pregnant women of the potential risk to the fetus. First trimester: Highest risk of major congenital malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to MMAE's anti-mitotic effects.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
No data on presence of enfortumab vedotin or its metabolites in human milk. M/P ratio unknown. Because many drugs are excreted in human milk and due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. The drug should be avoided during pregnancy unless the benefit outweighs risks. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure, but no dose adjustment guidelines exist.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody-drug conjugate used in locally advanced or metastatic urothelial carcinoma. Monitor for peripheral neuropathy, skin reactions, and hyperglycemia. Premedicate with antihistamines and antipyretics to reduce infusion reactions. Dose reductions may be needed for Grade 3 or higher adverse events.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Report any new or worsening numbness, tingling, or pain in hands or feet immediately.,Monitor for signs of skin reactions such as rash, itching, or blisters, and avoid sun exposure.,Check blood glucose regularly if you have diabetes or are at risk for hyperglycemia.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Avoid live vaccines during treatment.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PADCEV vs AURLUMYN, answered by our medical review team.
PADCEV is a Antineoplastic Agent that works by Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PADCEV and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PADCEV is: 1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PADCEV and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PADCEV is classified as Category C. PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Ad. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.